Ayala Pharmaceuticals Inc (ADXS)

[fbg0316]

Agree that we need a development on the business end. The science and platform at ADXS has always been strong, and this latest PSA data is more confirmation of such and validates why we chose to put money into the company. The problem has never been with the science. Rather the massive shareholder value destruction we have see has been from incompetent, unfocused and self-serving business management (which O'Connor master-minded and Ratsinsky rubber stamped, yet when it was clear O'Connor was driving the company into the ground and had to leave Ratsinsky had no contingency plan, which has since resulted in that much more investor losses).